ATE473283T1 - Dna-expressionsvektoren - Google Patents
Dna-expressionsvektorenInfo
- Publication number
- ATE473283T1 ATE473283T1 AT01980716T AT01980716T ATE473283T1 AT E473283 T1 ATE473283 T1 AT E473283T1 AT 01980716 T AT01980716 T AT 01980716T AT 01980716 T AT01980716 T AT 01980716T AT E473283 T1 ATE473283 T1 AT E473283T1
- Authority
- AT
- Austria
- Prior art keywords
- expression vectors
- dna expression
- vectors
- host cells
- intron
- Prior art date
Links
- 239000013604 expression vector Substances 0.000 title 1
- 239000013598 vector Substances 0.000 abstract 3
- 241000701024 Human betaherpesvirus 5 Species 0.000 abstract 1
- 108700002232 Immediate-Early Genes Proteins 0.000 abstract 1
- 229940065638 intron a Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000035897 transcription Effects 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0027088.4A GB0027088D0 (en) | 2000-11-06 | 2000-11-06 | DNA expression vectors |
| PCT/GB2001/004912 WO2002036792A2 (en) | 2000-11-06 | 2001-11-02 | Dna expression vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE473283T1 true ATE473283T1 (de) | 2010-07-15 |
Family
ID=9902639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01980716T ATE473283T1 (de) | 2000-11-06 | 2001-11-02 | Dna-expressionsvektoren |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20040082531A1 (de) |
| EP (1) | EP1334201B1 (de) |
| JP (1) | JP2004512837A (de) |
| AT (1) | ATE473283T1 (de) |
| AU (1) | AU2002212505A1 (de) |
| CA (1) | CA2427952A1 (de) |
| DE (1) | DE60142519D1 (de) |
| ES (1) | ES2346850T3 (de) |
| GB (1) | GB0027088D0 (de) |
| WO (1) | WO2002036792A2 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004024183A1 (en) * | 2002-09-12 | 2004-03-25 | Pharmexa A/S | Immunization against autologous ghrelin |
| GB0225786D0 (en) * | 2002-11-05 | 2002-12-11 | Glaxo Group Ltd | Vaccine |
| GB0225788D0 (en) * | 2002-11-05 | 2002-12-11 | Glaxo Group Ltd | Vaccine |
| US20040146486A1 (en) * | 2003-01-24 | 2004-07-29 | Juan Sun | Hybrid vector system for use as a vaccine |
| GB0321615D0 (en) | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
| WO2005035771A2 (en) | 2003-10-10 | 2005-04-21 | Powderject Vaccines, Inc. | Nucleic acid constructs |
| GB0400965D0 (en) * | 2004-01-16 | 2004-02-18 | Glaxo Group Ltd | Promoter |
| US7785875B2 (en) * | 2004-07-03 | 2010-08-31 | Mogam Biotechnology Research Institute | Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same |
| EP1799256A4 (de) * | 2004-08-27 | 2009-10-21 | 3M Innovative Properties Co | Verfahren zur auslösung einer immunantwort gegen hiv |
| WO2006026470A2 (en) * | 2004-08-27 | 2006-03-09 | 3M Innovative Properties Company | Hiv immunostimulatory compositions |
| US7429480B2 (en) * | 2005-01-10 | 2008-09-30 | National Taiwan University | Promoter sequences from WSSV immediate early genes and their uses in recombinant DNA techniques |
| WO2006076678A2 (en) * | 2005-01-13 | 2006-07-20 | The Johns Hopkins University | Prostate stem cell antigen vaccines and uses thereof |
| GB0507997D0 (en) * | 2005-02-01 | 2005-05-25 | Powderject Vaccines Inc | Nucleic acid constructs |
| US8008467B2 (en) * | 2005-09-08 | 2011-08-30 | The Research Foundation For Microbial Diseases Of Osaka University | Promoter for introducing a gene into a lymphocyte or blood cell and application thereof |
| JP5222289B2 (ja) | 2006-07-18 | 2013-06-26 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | マラリア用ワクチン |
| CL2007003743A1 (es) | 2006-12-22 | 2008-07-11 | Bayer Cropscience Ag | Composicion que comprende fenamidona y un compuesto insecticida; y metodo para controlar de forma curativa o preventiva hongos fitopatogenos de cultivos e insectos. |
| CN103550764A (zh) | 2007-03-02 | 2014-02-05 | 葛兰素史密丝克莱恩生物有限公司 | 疫苗组合物及其在刺激免疫反应中的用途 |
| GB0710538D0 (en) * | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Vaccine |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5168062A (en) * | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| FR2735789B1 (fr) * | 1995-06-23 | 1997-07-25 | Centre Nat Rech Scient | Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant |
| KR20000006334A (ko) * | 1998-06-26 | 2000-01-25 | 이선경 | 바이러스코딩염기서열이전혀없는고효율레트로바이러스벡터 |
| CN1247785C (zh) * | 2000-10-13 | 2006-03-29 | 希龙公司 | 巨细胞病毒内含子a片段 |
-
2000
- 2000-11-06 GB GBGB0027088.4A patent/GB0027088D0/en not_active Ceased
-
2001
- 2001-11-02 CA CA002427952A patent/CA2427952A1/en not_active Abandoned
- 2001-11-02 AU AU2002212505A patent/AU2002212505A1/en not_active Abandoned
- 2001-11-02 WO PCT/GB2001/004912 patent/WO2002036792A2/en not_active Ceased
- 2001-11-02 ES ES01980716T patent/ES2346850T3/es not_active Expired - Lifetime
- 2001-11-02 JP JP2002539538A patent/JP2004512837A/ja active Pending
- 2001-11-02 DE DE60142519T patent/DE60142519D1/de not_active Expired - Lifetime
- 2001-11-02 EP EP01980716A patent/EP1334201B1/de not_active Expired - Lifetime
- 2001-11-02 US US10/415,999 patent/US20040082531A1/en not_active Abandoned
- 2001-11-02 AT AT01980716T patent/ATE473283T1/de not_active IP Right Cessation
-
2007
- 2007-03-07 US US11/683,194 patent/US20090130126A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004512837A (ja) | 2004-04-30 |
| US20040082531A1 (en) | 2004-04-29 |
| WO2002036792A3 (en) | 2002-09-06 |
| GB0027088D0 (en) | 2000-12-20 |
| DE60142519D1 (de) | 2010-08-19 |
| AU2002212505A1 (en) | 2002-05-15 |
| CA2427952A1 (en) | 2002-05-10 |
| EP1334201A2 (de) | 2003-08-13 |
| US20090130126A1 (en) | 2009-05-21 |
| ES2346850T3 (es) | 2010-10-21 |
| WO2002036792A2 (en) | 2002-05-10 |
| EP1334201B1 (de) | 2010-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60142519D1 (de) | Dna-expressionsvektoren | |
| DE50312946D1 (de) | Difluormethyl thiazolyl carboxanilide | |
| HUP0001293A1 (hu) | Heterociklusos vegyületek és ezeket tartalmazó gyógyászati készítmények béta-amiloid-peptidek gátlására | |
| PT966465E (pt) | Inibidores do enzima imfdh | |
| NO992102L (no) | Peptidblanding, samt farmasøytisk sammensetning og kreftvaksine som innbefatter peptidblandingen | |
| DE60128149D1 (en) | Putrescin-n-methyltransferasepromotor | |
| WO2002044320A3 (en) | Human elongase genes and uses thereof | |
| AP2001002104A0 (en) | Genes of the 1-desoxy-d-xylulose biosynthetic pathway. | |
| DE60118798D1 (de) | Fragmente der intron a von citomegalovirus | |
| CY1105398T1 (el) | 5΄ ESTs ΓΙΑ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ ΠΟΥ ΕΚΦΡΑΖΟΝΤΑΙ ΣΕ ΔΙΑΦΟΡΟΥΣ ΙΣΤΟΥΣ | |
| ATE440960T1 (de) | T-helferzellen-epitope | |
| SG142300A1 (en) | Promoters for expression in modified vaccinia virus ankara | |
| NO20022149D0 (no) | Ikke-viralt genleveringssystem | |
| TR200102655T2 (tr) | Dört L. infantum proteininin antijen belirleyicilerini kodlayan kimerik gen. | |
| FR2744455B1 (fr) | Nouvelles sequences d'acides nucleiques de la famille des facteurs suppresseurs de tumeurs, produits d'expression correspondants et leurs applications | |
| DE69831737D1 (de) | Neurotrypsin | |
| ATE247130T1 (de) | Inhibitoren für den urokinaserezeptor | |
| EP1565080A4 (de) | Neue immunogene proteine von leptospira | |
| CY1111004T1 (el) | Χρησιμες συνθεσεις για τη ρυθμιση της δρασης του γονιδιου της παρκινης | |
| WO2000052045A3 (en) | Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof | |
| NO20022148L (no) | Ikke-viralt genleveringssystem | |
| TR199802300T2 (xx) | �nsan G proteini �3 alt-birimindeki bir gendeki genetik d�n���m�n hastal�klar�n te�hisi i�in kullan�lmas�. | |
| GB2349150B (en) | Expression of DNA or proteins in C. Elegans | |
| ATE327987T1 (de) | Methylthiophencarboxanilide | |
| WO2001014415A3 (en) | Egfh2 genes and gene products |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |